These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33632832)

  • 1. SARS-CoV-2 dependence on host pathways.
    Wong JP; Damania B
    Science; 2021 Feb; 371(6532):884-885. PubMed ID: 33632832
    [No Abstract]   [Full Text] [Related]  

  • 2. Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy.
    Guisado-Vasco P; González-Cortijo L; D'Errico G; Serrera-Alvarez A; Sotres-Fernandez G; García-Coca M; Fernández-Sousa JM; Luepke-Estefan XE; López-Martín JA; Jimeno JM
    Ann Oncol; 2021 Oct; 32(10):1295-1297. PubMed ID: 34242743
    [No Abstract]   [Full Text] [Related]  

  • 3. Hundreds of COVID trials could provide a deluge of new drugs.
    Ledford H
    Nature; 2022 Mar; 603(7899):25-27. PubMed ID: 35233098
    [No Abstract]   [Full Text] [Related]  

  • 4. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly Discovered Host-Cell Factor Could Be a COVID-19 Treatment Target.
    Larkin H
    JAMA; 2023 Feb; 329(7):532. PubMed ID: 36723975
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
    Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.
    Prakash H; Upadhyay D; Bandapalli OR; Jain A; Kleuser B
    Prostaglandins Other Lipid Mediat; 2021 Feb; 152():106504. PubMed ID: 33147503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peripheral and core regions of virus-host network of COVID-19.
    Wang B; Dong X; Hu J; Ma X; Han C; Wang Y; Gao L
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 33956950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
    Bojkova D; Klann K; Koch B; Widera M; Krause D; Ciesek S; Cinatl J; Münch C
    Nature; 2020 Jul; 583(7816):469-472. PubMed ID: 32408336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Prediction of the Potential Target of SARS-CoV-2 Inhibitor Plitidepsin via Molecular Docking, Dynamic Simulations and MM-PBSA Calculations.
    El Hassab MA; Hemeda LR; Elsayed ZM; Al-Rashood ST; Abdel-Hamid Amin MK; Abdel-Aziz HA; Eldehna WM
    Chem Biodivers; 2022 Feb; 19(2):e202100719. PubMed ID: 34813168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarities and Dissimilarities of COVID-19 and Other Coronavirus Diseases.
    Fung TS; Liu DX
    Annu Rev Microbiol; 2021 Oct; 75():19-47. PubMed ID: 33492978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulating the host immune response to fight against COVID-19: Where are we in 2021?
    Hertanto DM; Sutanto H; Wiratama BS; Wungu CDK
    Virulence; 2021 Dec; 12(1):1732-1736. PubMed ID: 34224330
    [No Abstract]   [Full Text] [Related]  

  • 16. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
    Hum C; Loiselle J; Ahmed N; Shaw TA; Toudic C; Pezacki JP
    Drugs; 2021 Apr; 81(5):517-531. PubMed ID: 33638807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waves of SARS-CoV-2 Infection and Blood Coagulation-A Link and Beyond.
    Harenberg J; Violi F
    Thromb Haemost; 2021 Jan; 121(1):4-6. PubMed ID: 33477197
    [No Abstract]   [Full Text] [Related]  

  • 20. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.